Literature DB >> 12384456

LOX-1 inhibition in myocardial ischemia-reperfusion injury: modulation of MMP-1 and inflammation.

Dayuan Li1, Victor Williams, Ling Liu, Hongjiang Chen, Tatsuya Sawamura, Tamim Antakli, Jawahar L Mehta.   

Abstract

A recently identified lectin-like oxidized low-density lipoprotein receptor (LOX-1) mediates endothelial cell injury and facilitates inflammatory cell adhesion. We studied the role of LOX-1 in myocardial ischemia-reperfusion (I/R) injury. Anesthetized Sprague-Dawley rats were subjected to 60 min of left coronary artery (LCA) ligation, followed by 60 min of reperfusion. Rats were treated with saline, LOX-1 blocking antibody JXT21 (10 mg/kg), or nonspecific anti-goat IgG (10 mg/kg) before I/R. Ten other rats underwent surgery without LCA ligation and served as a sham control group. LOX-1 expression was markedly increased during I/R (P < 0.01 vs. sham control group). Simultaneously, the expression of matrix metalloproteinase-1 (MMP-1) and adhesion molecules (P-selectin, VCAM-1, and ICAM-1) was also increased in the I/R area (P < 0.01 vs. sham control group). There was intense leukocyte accumulation in the I/R area in the saline-treated group. Treatment of rats with the LOX-1 antibody prevented I/R-induced upregulation of LOX-1 and reduced MMP-1 and adhesion molecule expression as well as leukocyte recruitment. LOX-1 antibody, but not nonspecific IgG, also reduced myocardial infarct size (P < 0.01 vs. saline-treated I/R group). To explore the link between LOX-1 and adhesion molecule expression, we measured expression of oxidative stress-sensitive p38 mitogen-activated protein kinase (p38 MAPK). The activity of p38 MAPK was increased during I/R (P < 0.01 vs. sham control), and use of LOX-1 antibody inhibited p38 MAPK activation (P < 0.01). These findings indicate that myocardial I/R upregulates LOX-1 expression, which through p38 MAPK activation increases the expression of MMP-1 and adhesion molecules. Inhibition of LOX-1 exerts an important protective effect against myocardial I/R injury.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12384456     DOI: 10.1152/ajpheart.00382.2002

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  23 in total

1.  TLR4 activation and IL-6-mediated cross talk between adipocytes and mononuclear cells synergistically stimulate MMP-1 expression.

Authors:  Devadoss J Samuvel; Junfei Jin; Kamala P Sundararaj; Yanchun Li; Xiaoming Zhang; Maria F Lopes-Virella; Yan Huang
Journal:  Endocrinology       Date:  2011-09-27       Impact factor: 4.736

Review 2.  LOX-1, a new marker of risk and prognosis in coronary artery disease?

Authors:  Valter Lubrano; Silvana Balzan
Journal:  Mol Cell Biochem       Date:  2013-08-11       Impact factor: 3.396

3.  Chaperonin-containing TCP-1 complex directly binds to the cytoplasmic domain of the LOX-1 receptor.

Authors:  Deenadayalan Bakthavatsalam; Roh Hun Soung; David J Tweardy; Wah Chiu; Richard A F Dixon; Darren G Woodside
Journal:  FEBS Lett       Date:  2014-05-17       Impact factor: 4.124

4.  Abrogation of lectin-like oxidized LDL receptor-1 attenuates acute myocardial ischemia-induced renal dysfunction by modulating systemic and local inflammation.

Authors:  Jingjun Lu; Xianwei Wang; Wenze Wang; Harish Muniyappa; Abhishek Deshmukh; Changping Hu; Kumuda Das; Jawahar L Mehta
Journal:  Kidney Int       Date:  2012-08       Impact factor: 10.612

5.  Associations between Lectin-like, oxidized low-density lipoprotein receptor-1 G501C and 3'-UTR-C188T polymorphisms with coronary artery disease: a meta-analysis.

Authors:  Tian-Ying Feng; Hong-Wei Shan; Rui Lang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

6.  Generation and characterization of chicken monoclonal antibodies against human LOX-1.

Authors:  Shin Iwamoto; Norihisa Nishimichi; Yoshiko Tateishi; Yuko Sato; Hiroyuki Horiuchi; Shuichi Furusawa; Tatsuya Sawamura; Haruo Matsuda
Journal:  MAbs       Date:  2009 Jul-Aug       Impact factor: 5.857

Review 7.  Role of oxidative stress-related biomarkers in heart failure: galectin 3, α1-antitrypsin and LOX-1: new therapeutic perspective?

Authors:  Valter Lubrano; Silvana Balzan
Journal:  Mol Cell Biochem       Date:  2019-11-29       Impact factor: 3.396

8.  Plasma L5 levels are elevated in ischemic stroke patients and enhance platelet aggregation.

Authors:  Ming-Yi Shen; Fang-Yu Chen; Jing-Fang Hsu; Ru-Huei Fu; Chia-Ming Chang; Chiz-Tzung Chang; Chung-Hsiang Liu; Jia-Rong Wu; An-Sheng Lee; Hua-Chen Chan; Joen-Rong Sheu; Shinn-Zong Lin; Woei-Cherng Shyu; Tatsuya Sawamura; Kuan-Cheng Chang; Chung Y Hsu; Chu-Huang Chen
Journal:  Blood       Date:  2015-12-17       Impact factor: 22.113

Review 9.  Clinical and Preclinical Use of LOX-1-Specific Antibodies in Diagnostics and Therapeutics.

Authors:  Jonathan De Siqueira; Izma Abdul Zani; David A Russell; Stephen B Wheatcroft; Sreenivasan Ponnambalam; Shervanthi Homer-Vanniasinkam
Journal:  J Cardiovasc Transl Res       Date:  2015-09-18       Impact factor: 4.132

10.  Integrated transcriptomic analysis of human tuberculosis granulomas and a biomimetic model identifies therapeutic targets.

Authors:  Michaela T Reichmann; Liku B Tezera; Andres F Vallejo; Milica Vukmirovic; Rui Xiao; James Reynolds; Sanjay Jogai; Susan Wilson; Ben Marshall; Mark G Jones; Alasdair Leslie; Jeanine M D'Armiento; Naftali Kaminski; Marta E Polak; Paul Elkington
Journal:  J Clin Invest       Date:  2021-08-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.